BNP Paribas Financial Markets Boosts Holdings in AxoGen, Inc. (NASDAQ:AXGN)

BNP Paribas Financial Markets grew its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 238.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,284 shares of the medical equipment provider’s stock after purchasing an additional 8,656 shares during the period. BNP Paribas Financial Markets’ holdings in AxoGen were worth $172,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in AXGN. Quest Partners LLC lifted its position in AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of AxoGen during the 3rd quarter valued at $56,000. Koss Olinger Consulting LLC bought a new stake in shares of AxoGen during the 2nd quarter worth $75,000. Acadian Asset Management LLC purchased a new position in AxoGen in the second quarter worth $125,000. Finally, Oppenheimer & Co. Inc. bought a new position in AxoGen in the third quarter valued at $156,000. Institutional investors own 80.29% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, AxoGen presently has an average rating of “Buy” and a consensus price target of $15.00.

AxoGen Price Performance

Shares of NASDAQ:AXGN opened at $14.74 on Wednesday. The company’s fifty day moving average is $13.83 and its 200 day moving average is $11.56. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $15.90. The stock has a market cap of $648.68 million, a PE ratio of -46.06 and a beta of 1.06.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.